Circulating Cell-Derived Microparticles in Crohn?s Disease

Abstract

Procoagulant membrane microparticles can be released from activated or apoptotic cells in response to various environmental stimuli. The aim of this study was to investigate the presence of microparticles in Crohn's disease and to assess their variations after infliximab therapy. We compared the levels of circulating microparticles in 38 patients with Crohn's disease, 16 patients with ulcerative colitis, 7 patients with infectious colitis, and 17 control subjects. The evolution of microparticle levels was assessed after infliximab therapy in 13 patients with Crohn's disease. Circulating microparticle levels were elevated in patients with Crohn's disease (9.31+/-0.66 nmol/L phosphatidylserine equivalent [PS Eq]) or infectious colitis (10.71+/-0.92 nmol/L PS Eq) compared to patients with ulcerative colitis (5.75+/-0.59 nmol/L PS Eq) and control subjects (4.06+/-0.37 nmol/L PS Eq) (P = 0.001). Infliximab induced a significant diminution of the amounts of circulating microparticles, from 10.33+/-1.20 to 6.45+/-0.90 nmol/L PS Eq (P = 0.002). Generation of circulating microparticles occurs in Crohn's disease; infliximab induces significant diminution. Release of microparticles could be linked to the type of inflammatory response underlying Crohn's disease.

Increased levels of circulating platelet derived microparticles in Crohn's disease patients

“…Nevertheless, ELISA involves soluble GPs, i.e., GPIb/IX/V complex; hence possibly overestimating PDMPs quantification. In the study by Chamouard et al, [14] PDMPs levels did not differ among the patients groups. Their principal investigating modality was an immunocapture assay measuring prothrombinase activity MPs; therefore, examining only pro-coagulant MPs (Annexin Vþ).…”

“…[17] Correlation between PDMPs levels and inflammation activity was reported by Andoh et al [13] Lionetti et al [17] also correlated PDMPs expression and IBD clinical activity in a small cohort of CD patients. Conversely, the remaining studies results [14][15][16] do not favor a relationship between PMDPs levels and IBD activity. Noticeably, there was no correlation between PDMPs expression with CRPeven high sensitive CRP -in none of those studies.…”

“…Andoh et al [13] Chamouard et al [14] Palkovits et al [ As estimated in each study. b As described and performed in each study.…”

“…Previous studies revealed overall elevated PDMPs levels in IBD compared to healthy controls (Table 3 summarizes data from available studies). [13][14][15][16][17] However, to the best of our knowledge, unanswered remains the question as to whether established IBD medication treatments pose any impact on PDMPs levels. Our work illustrates that (i) there is significant increase of studied PDMPs levels, including those bearing exposed phosphatidylserine in CD patients compared to healthy individuals.…”

“…These observations have prompted to investigation of PDMPs in IBD [13][14][15][16][17] with major inconsistencies among their results, mainly due to differences in the studied populations and in the methodical approaches applied. To this end, we conducted a study aiming to evaluate the levels of circulating PDMPs and PDMPs expressing Annexin V in peripheral blood of IBD patients using flow cytometry and to compare them to those of healthy individuals.…”